Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Rogier Hintzen, Michelle Mellion et al.|The Lancet Neurology|2019Cited by 185
The 11-year long-term follow-up study from the randomized BENEFIT CIS trialLudwig Kappos, Christine Lebrun‐Frénay, Gilles Edan et al.|Neurology|2016Cited by 130
Adult-onset autosomal dominant centronuclear myopathy due to BIN1 mutationsJohann Böhm, Jocelyn Laporte, Ana Lía Taratuto et al.|Brain|2014Cited by 103
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosisMathilde Lefort, F. Grand’Maison, Sifat Sharmin et al.|BMC Medical Research Methodology|2022Cited by 6